Inno-206
Stage IV Appendix Carcinoma AJCC v8
City of Hope Medical CenterPhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 95/ 100
Competitive context
6 Active assets in the Stage IV Appendix Carcinoma AJCC v8 cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
MITOMYCIN C City of Hope Medical Center | Phase 3 | BB |
FLUOROURACILUM City of Hope Medical Center | Phase 3 | BB |
Irinotecan City of Hope Medical Center | Phase 3 | BB |
Thalidomide Wake Forest University Health Sciences | Phase 2 | B |
Palonosetron Alliance for Clinical Trials in Oncology | Phase 2 | CCC |
View all 17 →
Same molecule, other indications
Inno-206 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →